Search PubMed⌕ Search

Biomedical subjects

B Fritzell

Publications and source records attributed to B Fritzell.

At least 55 records · Page 3Linked to original sources
PubMed1988

Treatment of spasmodic dysphonia by means of resection of the recurrent laryngeal nerve.

Over the last twelve years 44 patients suffering from spasmodic dysphonia have been seen at Huddinge hospital. There were 34 women and 10 men. 22 of these patients were for various reasons not regarded as candidates for surgery. The opposite applied to the remaining 22 patients. The outcome of a temporary nerve block guided us (the surgeons and the patients) whether to operate or not. 12 patients were thus operated upon by means of resection of the right recurrent laryngeal nerve. The immediate post-operative result was excellent in 11 of 12 patients but the voice deteriorated in 4 patients. They had revision surgery with a successful result in 3 of them. Also the other 7 patients deteriorated to some extent but not to the degree that revision surgery was necessary. It is our hypothesis that recurrencies are caused by reinnervation of the sectioned nerve.

Female↗
PubMed1986

[Evaluation of thermostable yellow fever vaccine from the Pasteur Institute on international travellers].

The authors studied the tolerance and efficacy of the new stabilized 17D yellow fever vaccine produced by Pasteur Vaccins, on 50 international travellers at the University Hospital of Grenoble (France), comparing it with the standard 17D yellow fever vaccine. The short-term and long-term tolerance in all the travellers was excellent. The serological efficacy was estimated by seroneutralization assay with the vaccine virus Rockefeller 17D, which is the most sensitive and the most specific method. The seroconversion rate was 93.8%, the same as the rate obtained with the standard yellow fever vaccine in 50 other travellers. The authors studied also the serological response to the standard yellow fever vaccine associated with other vaccines (diphtheria, tetanus, oral or injectable poliomyelitis, and oral cholera): the seroconversion rates were similar to those obtained with the yellow fever vaccine alone, thus demonstrating that these associated vaccines do not interfere with immunization against yellow fever.

Drug Tolerance↗
PubMed1986

Comparative clinical study of a new 17D thermostable yellow fever vaccine.

The immunogenicity and the safety of a new heat-stable 17D yellow fever vaccine have been assessed in a randomized comparative study by reference to a non-stabilized vaccine preparation. Seronegative adults were used and 115 and 143 were given the heat-stable and the non-stabilized vaccine, respectively. Fifty two days after the immunization, haemagglutination inhibiting antibodies were found in 77.6 and 73.9% of the vaccinees, neutralizing antibodies in 99.3 and 100% of them. The percentage of seroconversion and the geometric mean of antibody titres were not significantly different. No complaints or adverse reactions in association with the vaccines were recorded. This study demonstrates the high immunogenicity of this new stabilized vaccine whose stability has already been proven.

Adult↗
PubMed1985

Thermostability and efficacy in the field of a new, stabilized yellow fever virus vaccine.

Samples of the new, stabilized 17D virus vaccine from Pasteur Vaccins, France were stored for up to six months at +10 +/- 2 degrees C in the hospital of Bouar, Central African Republic. Each month during this study, the vaccine ampoules were put into an ice box without ice and taken into the field to be used as part of a vaccination programme. No significant loss of infectious virus titre was observed under these conditions. Efficacy of the vaccine was determined from percent seroconversions in vaccinated children. No loss of efficacy of the vaccine was observed after five months storage at +10 degrees C and five trips in the field, confirming the high heat stability of the new vaccine.

Antibodies, Viral↗
PubMed1984

Teflon injection in 16 patients with paralytic dysphonia: perceptual and acoustic evaluations.

Sixteen patients with paralytic dysphonia were treated with Teflon injection in the paralyzed vocal fold. Trained voice pathologists rated the pre- and postinjection voices on a 5-point scale for each 11 voice characteristics. Among these, aphonia, breathiness, and hypofunction diminished significantly after injection. The perceptual evaluation was correlated with acoustic data from long-time-average spectrum analysis, fundamental frequency distribution analysis, and waveform perturbation analysis. In this acoustic assessment, systematic changes were found in the long-time-average spectra, which agreed well with the perceptual data. In 12 of 16 patients the voice was both perceptually and acoustically improved after Teflon injection.

Adult↗